The approval removes the binary FDA risk and shifts focus to launch execution and IGNYTE-3 confirmatory trial enrollment (primary endpoint readout expected 2030). Monitor initial prescription trends and reimbursement dynamics over the next 60 days. The $150M offering at $12.06/share creates ~13% dilution but was necessary to fund commercialization.
Price Chart
Executive Summary
Replimune reported fiscal Q1 2027 results with an in-line net loss of $69.8M ($-0.72 EPS), but the headline is the FDA accelerated approval of TUDRIQEV (RP1) on August 6, 2026, transforming the company into a commercial-stage biotech. A concurrent $150M financing extends cash runway beyond 12 months to support the U.S. launch within 60 days and the IGNYTE-3 confirmatory trial.
Key Financial Metrics
Key Facts
- FDA granted accelerated approval for TUDRIQEV (RP1) + nivolumab in advanced melanoma on August 6, 2026; launch within 60 days
- Net loss improved to $69.8M in Q1 FY2027 from $86.7M in the prior-year quarter
- EPS of $-0.72 matched consensus of $-0.72 (in-line)
- Cash, cash equivalents and short-term investments were $195.3M at June 30, 2026; plus $141M net proceeds from August offering extends runway >12 months
- Michelle DiNapoli appointed Chief Commercial Officer effective August 18, 2026
- R&D expenses decreased to $49.3M from $57.8M; SG&A decreased to $19.0M from $32.6M year-over-year
Financial Impact
Transformational: first approved product enables revenue generation; $150M financing ($141M net) provides capital for launch and confirmatory trial
Risk Factors
- Accelerated approval contingent on verification of clinical benefit in IGNYTE-3; failure could lead to withdrawal
- Commercial execution risk as a first-time product launcher
- Baker Brothers resale registration (S-3/A) creates ~30% overhang on common stock
- Competition from other oncolytic viruses and immunotherapies in melanoma
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-096483 |
| Document: tm2623208d1_8k.htm | 0001104659-26-096483 |
| Document: 0001104659-26-096483-index-headers.html | 0001104659-26-096483 |
| Document: 0001104659-26-096483-index.html | 0001104659-26-096483 |
| Document: 0001104659-26-096483.txt | 0001104659-26-096483 |
| 8-K Data (Synthetic) | 0001104659-26-096483 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 5w ago | Press Release | $14.71 $13.07 | ▲ +11.15% | ▲ +11.16% | $13.04 (+11.35%) |
Aug 19, 2026 6w ago | Insider Cluster | $14.05 $13.07 | ▼ −6.98% | ▼ −6.98% | $13.04 (−7.19%) |
Aug 14, 2026 7w ago | 8-K | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 14, 2026 7w ago | Press Release | $14.97 $13.11 | ▼ −12.42% | ▼ −10.43% | $13.04 (−12.89%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 12, 2026 7w ago | Insider Cluster | $15.19 $12.92 | ▼ −14.94% | ▼ −13.20% | $13.04 (−14.15%) |
Aug 10, 2026 7w ago | Press Release | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 8-K | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 10, 2026 7w ago | 424B5 | $13.67 $14.77 | ▼ −8.05% | ▼ −8.96% | $13.04 (+4.61%) |
Aug 7, 2026 8w ago | 8-K | $12.06 $15.04 | ▲ +24.71% | ▲ +25.11% | $13.04 (+8.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access